Cargando…
Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α
INTRODUCTION: Bu-Shen-Ning-Xin decoction (BSNXD) is a traditional Chinese medicinal composition that has been used as a remedy for postmenopausal osteoporosis, but the mechanisms affecting bone metabolism are not fully understood. PURPOSE: We investigated the molecular mechanism and signaling pathwa...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516212/ https://www.ncbi.nlm.nih.gov/pubmed/26229438 http://dx.doi.org/10.2147/DDDT.S88512 |
_version_ | 1782383031775920128 |
---|---|
author | Wang, Ling Qiu, Xue-Min Gui, Yu-Yan Xu, Ying-Ping Gober, Hans-Jürgen Li, Da-Jin |
author_facet | Wang, Ling Qiu, Xue-Min Gui, Yu-Yan Xu, Ying-Ping Gober, Hans-Jürgen Li, Da-Jin |
author_sort | Wang, Ling |
collection | PubMed |
description | INTRODUCTION: Bu-Shen-Ning-Xin decoction (BSNXD) is a traditional Chinese medicinal composition that has been used as a remedy for postmenopausal osteoporosis, but the mechanisms affecting bone metabolism are not fully understood. PURPOSE: We investigated the molecular mechanism and signaling pathway underlying the effect of BSNXD on osteoclastogenesis. MATERIALS AND METHODS: A postmenopausal osteoporosis animal model generated by ovariectomy was administered BSNXD and drug-derived serum was prepared. An enzyme immunoassay was conducted to measure the 17-β-estradiol (E2) concentration in the drug-derived serum. Bone marrow-derived monocyte/macrophage precursor cells were treated with drug-derived serum, and tartrate-resistance acid phosphatase staining was conducted to observe osteoclastogenesis. A bone resorption assay was performed to analyze the effect on osteoclastic resorptive function. Real-time PCR, flow cytometry, Western blotting, transfection, and luciferase assays were conducted to explore the related mechanism. RESULTS: E2 was not elevated in BSNXD-derived serum. BSNXD-derived serum suppressed receptor activation of nuclear factor κB ligand (RANKL)-activated osteoclastogenesis in a dose-dependent manner; this effect could be reversed by estrogen receptor α antagonist methyl-piperidino-pyrazole. The serum suppressed RANKL-induced NF-κB transcription and inhibited the accumulation of nuclear factor of activated T-cells, cytoplasmic 1 in osteoclast precursor cells; the inhibitory effect was abolished by methyl-piperidino-pyrazole but not the estrogen receptor β antagonist or androgen receptor antagonist. CONCLUSION: These results collectively suggest that administration of BSNXD presents inhibitory effects on osteoclast differentiation by abrogating the RANKL-induced nuclear factor of activated T-cells, cytoplasmic 1 and NF-κB signaling pathways downstream of estrogen receptor α, thereby contributing to the inhibitory effect on bone resorption. |
format | Online Article Text |
id | pubmed-4516212 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-45162122015-07-30 Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α Wang, Ling Qiu, Xue-Min Gui, Yu-Yan Xu, Ying-Ping Gober, Hans-Jürgen Li, Da-Jin Drug Des Devel Ther Original Research INTRODUCTION: Bu-Shen-Ning-Xin decoction (BSNXD) is a traditional Chinese medicinal composition that has been used as a remedy for postmenopausal osteoporosis, but the mechanisms affecting bone metabolism are not fully understood. PURPOSE: We investigated the molecular mechanism and signaling pathway underlying the effect of BSNXD on osteoclastogenesis. MATERIALS AND METHODS: A postmenopausal osteoporosis animal model generated by ovariectomy was administered BSNXD and drug-derived serum was prepared. An enzyme immunoassay was conducted to measure the 17-β-estradiol (E2) concentration in the drug-derived serum. Bone marrow-derived monocyte/macrophage precursor cells were treated with drug-derived serum, and tartrate-resistance acid phosphatase staining was conducted to observe osteoclastogenesis. A bone resorption assay was performed to analyze the effect on osteoclastic resorptive function. Real-time PCR, flow cytometry, Western blotting, transfection, and luciferase assays were conducted to explore the related mechanism. RESULTS: E2 was not elevated in BSNXD-derived serum. BSNXD-derived serum suppressed receptor activation of nuclear factor κB ligand (RANKL)-activated osteoclastogenesis in a dose-dependent manner; this effect could be reversed by estrogen receptor α antagonist methyl-piperidino-pyrazole. The serum suppressed RANKL-induced NF-κB transcription and inhibited the accumulation of nuclear factor of activated T-cells, cytoplasmic 1 in osteoclast precursor cells; the inhibitory effect was abolished by methyl-piperidino-pyrazole but not the estrogen receptor β antagonist or androgen receptor antagonist. CONCLUSION: These results collectively suggest that administration of BSNXD presents inhibitory effects on osteoclast differentiation by abrogating the RANKL-induced nuclear factor of activated T-cells, cytoplasmic 1 and NF-κB signaling pathways downstream of estrogen receptor α, thereby contributing to the inhibitory effect on bone resorption. Dove Medical Press 2015-07-21 /pmc/articles/PMC4516212/ /pubmed/26229438 http://dx.doi.org/10.2147/DDDT.S88512 Text en © 2015 Wang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Wang, Ling Qiu, Xue-Min Gui, Yu-Yan Xu, Ying-Ping Gober, Hans-Jürgen Li, Da-Jin Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α |
title | Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α |
title_full | Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α |
title_fullStr | Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α |
title_full_unstemmed | Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α |
title_short | Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α |
title_sort | bu-shen-ning-xin decoction: inhibition of osteoclastogenesis by abrogation of the rankl-induced nfatc1 and nf-κb signaling pathways via selective estrogen receptor α |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516212/ https://www.ncbi.nlm.nih.gov/pubmed/26229438 http://dx.doi.org/10.2147/DDDT.S88512 |
work_keys_str_mv | AT wangling bushenningxindecoctioninhibitionofosteoclastogenesisbyabrogationoftheranklinducednfatc1andnfkbsignalingpathwaysviaselectiveestrogenreceptora AT qiuxuemin bushenningxindecoctioninhibitionofosteoclastogenesisbyabrogationoftheranklinducednfatc1andnfkbsignalingpathwaysviaselectiveestrogenreceptora AT guiyuyan bushenningxindecoctioninhibitionofosteoclastogenesisbyabrogationoftheranklinducednfatc1andnfkbsignalingpathwaysviaselectiveestrogenreceptora AT xuyingping bushenningxindecoctioninhibitionofosteoclastogenesisbyabrogationoftheranklinducednfatc1andnfkbsignalingpathwaysviaselectiveestrogenreceptora AT goberhansjurgen bushenningxindecoctioninhibitionofosteoclastogenesisbyabrogationoftheranklinducednfatc1andnfkbsignalingpathwaysviaselectiveestrogenreceptora AT lidajin bushenningxindecoctioninhibitionofosteoclastogenesisbyabrogationoftheranklinducednfatc1andnfkbsignalingpathwaysviaselectiveestrogenreceptora |